Endocyte (ECYT) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Endocyte Reports First Quarter 2015 Financial Results and Provides Update on Clinical Progress
May 7, 2015 4:02 PM EDT- Dose Escalation for EC1456 and EC1169 Move to Fifth Dosing Cohorts Evaluating Two Schedules for Each Agent -
- Conference Call Today at 4:30 p.m. EDT -
WEST LAFAYETTE, Ind., May 7, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq: ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced financial results for the first quarter ending March 31, 2015, and provided a clinical update.
"We have successfully moved both EC1456, a folate-targeted tubulysin, and EC1169, a... More
